The phase 2 REDICAE trial (NCT05964738) randomised 98 stable and euvolemic outpatients with HFrEF 1:1 to diuretic withdrawal or maintenance [1]. The primary endpoint was perceived dyspnoea at 24 weeks, as was assessed by a visual analogue scale.
At 24 weeks, there was no difference in perceived dyspnoea between participants in the withdrawal arm and those in the control arm (least-square mean difference 2 mm; 95% CI -1.8 to +4.9; P=0.37). Similarly, there was no association between diuretic withdrawal and worsening HF events. “We also did not see any differences with respect to congestion parameters, such as NT-proBNP, between both arms of the study,” added Dr Jesus Torres Zamudio (Reina Sofia University Hospital Cordoba, Spain).
Discontinuation of diuretics in stable euvolemic outpatients with HFrEF on guideline-directed medical therapy did not lead to increased perceived dyspnoea or a higher incidence of HF events. Moreover, there was no association between diuretic withdrawal and quality-of-life or exercise capacity. “The sample size of this study was rather small compared with other HF trials,” Dr Torres Zamudio addressed the limitations of the REDICAE trial. “Also, a non-inferiority design may have been more appropriate given the study’s research question.”
- Torres Zamudio JA, et al. Safety and tolerability of diuretics withdrawal in patients with heart failure with reduced ejection fraction: REDICAE trial. Late-breaking clinical trials in chronic heart failure, Heart Failure 2025, 17–20 May, Belgrade, Serbia.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency? Next Article
Digifab may decrease kidney injury in high-risk cardiac surgery patients »
« PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency? Next Article
Digifab may decrease kidney injury in high-risk cardiac surgery patients »
Table of Contents: HFA 2025
Featured articles
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
Gene Therapy and the Future of HF Management
Artificial intelligence in HF management
Consistent results for nexiguran ziclumeran across wildtype and variant ATTR-CM
New gene therapy for HFrEF passes phase 1 testing
MUSIC-HFpEF: Encouraging early results of novel gene therapy for HFpEF
Innovative Devices
FUTURE-HF: Novel IVC sensor may help control volume and improve function outcomes
C-MIC II: Cardiac microcurrent therapy in HFrEF
Updates on Finerenone
Real-world eligibility for finerenone: insights from the FIDELITY pooled analysis
FINEARTS-HF confirms: analysis suggests premature cessation of Finerenone is associated with risk and supports long-term treatment
FIVE-STAR: Mechanistic effects of finerenone in T2D plus CKD unravelled
New Therapies for Hypertrophic Cardiomyopathy
SEQUOIA-HCM: Aficamten effects consistent across regions
Large Trials, Big Impact
PRAISE-HFrEF: Is it safe to use GLP1-receptor agonists in clinically severe HF?
HELIOS-B: Health benefits of vutrisiran for ATTR-CM may increase over time
EMPEROR-Preserved: Diastolic dysfunction might predict response to empagliflozin
GALACTIC-HF: zooming in on efficacy data and subgroups
More Hot Trials from HFA
PREFER-HF: Is iron therapy helpful in HFpEF with iron deficiency?
SOGALDI-PEF: SGLT2 inhibitor plus MRA improves biomarker outcomes in HFp/mrEF
REDICAE: Diuretic withdrawal appears feasible in stable HFrEF
GLADIATOR: Anti-ulcer agent geranylgeranylacetone explored in HFpEF
High vs low positive end-expiratory pressure in IMV may impact survival
Related Articles
August 19, 2021
Proenkephalin: A useful biomarker for new-onset heart failure?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
